Results 121 to 130 of about 21,795 (202)

Transthyretin Cardiac Amyloidosis and Heart Failure: State-of-the-Art Review and Practice Guidance. [PDF]

Rev Cardiovasc Med
Bukhari S, Hamza M, Malik A.
europepmc   +1 more source

Clinical and genetic features of hereditary transthyretin amyloidosis with polyneuropathy in China: insights from case analysis and literature review. [PDF]

Front Genet
Yuan X, Lv Y, Wang X, Han B, Xie B.
europepmc   +1 more source

Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score-Weighted Cohort Study. [PDF]

J Am Heart Assoc
Zmuda L, Zaroui A, Kharoubi M, Boutin E, Roca F, Oghina S, Teiger E, Laurent M, Canoui-Poitrine F, Damy T, Broussier A.   +10 more
europepmc   +1 more source

Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study. [PDF]

J Am Heart Assoc
Sperry BW, Masri A, Soman P, Ejaz AU, Bhattacharya P, Medoff B, Chandrashekar P, Ives L, Mirabal Santos A, Teruya SL, Wu Y, Zhao Y, Wang X, Maurer MS, Hanna M.   +14 more
europepmc   +1 more source

Bridging innovation and access: integrating cardiac amyloidosis into health system strengthening in the Americas. [PDF]

Lancet Reg Health Am
Zavaleta-Monestel E, Mora-Jiménez J, Arguedas-Chacón S, Salas-Segura J.   +3 more
europepmc   +1 more source

Invasive pressure-volume loop and PET-MR phenotyping in transthyretin cardiac amyloidosis: a multimodal imaging case report. [PDF]

Eur Heart J Case Rep
Venkateshvaran A, Pilebro B, Arvidsson S, Edbom F, Lindqvist P.   +4 more
europepmc   +1 more source

Transthyretin Amyloidosis

Journal of the American College of Cardiology, 2016
openaire   +1 more source

A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary. [PDF]

Future Cardiol
Wixner J, Dispenzieri A, Amass L, Carlsson M, Riley S, Powers E, Kelly JW.   +6 more
europepmc   +1 more source

Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis. [PDF]

JACC CardioOncol
Sideris K, Nelson TJ, Brinker L, Gao A, Tcheandjieu C, Kyriakopoulos CP, Berlowitz D, Hull L, Ferraro JP, Agiri FY, Pridgen KM, Roblin S, Joseph J, Damrauer SM, Chang KM, Teerlink CC, Stehlik J, Carter S, Lynch JA.   +18 more
europepmc   +1 more source